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Abstract
Utrophin is an autosomal paralogue of dystrophin, a protein whose deficit causes 
Duchenne and Becker muscular dystrophies (DMD/BMD). Utrophin is naturally over-
expressed at the sarcolemma of mature dystrophin- deficient fibres in DMD and BMD 
patients as well as in the mdx Duchenne mouse model. Dystrophin and utrophin can 
co- localise in human foetal muscle, in the dystrophin- competent fibres from DMD/BMD 
carriers, and revertant fibre clusters in biopsies from DMD patients. These findings sug-
gest that utrophin overexpression could act as a surrogate, compensating for the lack 
of dystrophin, and, as such, it could be used in combination with dystrophin restoration 
therapies. Different strategies to overexpress utrophin are currently under investigation. 
In recent years, many compounds have been reported to modulate utrophin expression 
efficiently in preclinical studies and ameliorate the dystrophic phenotype in animal mod-
els of the disease. In this manuscript, we discuss the current knowledge on utrophin pro-
tein and the different mechanisms that modulate its expression in skeletal muscle. We 
also include a comprehensive review of compounds proposed as utrophin regulators and, 
as such, potential therapeutic candidates for these muscular dystrophies.
K E Y W O R D S




Duchenne muscular dystrophy (DMD) is a fatal X- linked disorder 
that affects approximately one in 5000 live male births world-
wide. It is caused by one or more mutations in the DMD gene, 
which encodes dystrophin protein [1- 3]. This protein provides 
a structural link between the skeletal muscle cytoskeleton and 
the extracellular matrix, and it is essential to maintain muscle 
integrity. DMD patients appear clinically asymptomatic at birth; 
however, they manifest signs of muscle weakness and walking 
difficulties during early childhood when they are typically diag-
nosed. Loss of ambulation and wheelchair dependency ensues 
around puberty. Thanks to improvements in palliative care, life 
expectancy and quality of life have improved, and many patients 
may survive beyond 30 years of age [3]. Becker muscular dys-
trophy (BMD) is a milder dystrophy form caused by in- frame 
mutations in the DMD gene, leading to the expression of a 
shorter and partially functional dystrophin protein. Individuals 
with BMD share signs and symptoms with DMD patients, but 
they present a much later disease onset and a nearly average 
lifespan [4].
Although the molecular mechanisms of this disease have been 
extensively investigated, there is still no complete curative treat-
ment available. The current standard of care includes corticoids, 
such as prednisone or deflazacort, to delay disease progression [5]. 
Therapies based on dystrophin replacement at the protein or gene 
level are challenging due to the gene's large size, the wide distribu-
tion of the skeletal muscle throughout the body, and the possibility 
of immune response activation. However, many of these aspects 
have been overcome, and several micro- dystrophin gene therapies 
are currently undergoing clinical trials [6].
In recent years, regulatory agencies have conditionally approved 
several RNA treatments, based on read- through (ataluren [7]) or 
exon- skipping strategies (eteplirsen [8], golodirsen [9] and vilto-
larsen [10]). Nevertheless, these therapies are only applicable to a 
low percentage of DMD patients. Moreover, their delivery to the 
muscle is challenging [11], and their approval is controversial due to 
the low efficacy in dystrophin restoration and the limited clinical ef-
ficacy demonstrated so far [12].
Alternative strategies to mutation- specific approaches have 
been under intense investigation in several laboratories world-
wide in order to find a therapy applicable to the Becker and 
Duchenne community, regardless of their specific mutations. 
Among them, upregulation of utrophin, a structural and functional 
paralogue of dystrophin, is one of the most promising therapeu-
tic strategies. Recent studies based on high- throughput screening 
have identified small molecules able to induce utrophin upregu-
lation. However, utrophin expression is subject to regulation at 
multiple steps throughout its synthesis and degradation pathways, 
which need to be studied in depth to improve pharmacological 
interventions.
Utrophin vs dystrophin: structure, 
distribution and function
Dystrophin is a 427 kDa protein encoded by the DMD gene, the 
largest human gene, localised on the X chromosome. Utrophin, 
known initially as ‘dystrophin- related protein’, is a 395 kDa au-
tosomal paralogue of dystrophin encoded by the UTRN gene 
localised in the human chromosome 6q24 [13]. While four full- 
length dystrophin isoforms driven by different promoters have 
been described, only two full- length utrophin isoforms have 
been identified to date, utrophin A and B (Figure 1). These iso-
forms are transcribed from two different promoters, A and B. 
The two mRNAs vary at their 5’ ends, resulting in two identi-
cal functional proteins with slightly different N- terminal do-
mains and different expression patterns. While utrophin A is 
expressed in a variety of structures, including neuromuscular 
junctions, choroid plexus, pia mater and renal glomerulus [14], 
utrophin B remains restricted to the endothelial cells [15]. 
Interestingly, five novel 5’ utrophin isoforms (A’, B’, C, D and 
F) have been recently identified in human adult and embryonic 
tissues, but they remain to be fully characterised [16]. Both the 
DMD and the UTRN gene also encode for shorter dystrophin 
and utrophin transcripts. Shorter dystrophin isoforms, includ-
ing Dp260, Dp140, Dp116 and Dp71, have been identified in 
different non- muscle tissues such as the brain [17] and retina 
[18] (Figure 1A,C). Utrophin's internal promoters produce 
shorter transcripts such as Up71, Up140 and G- utrophin, which 
are expressed in many tissues with functions not fully under-
stood [19] (Figure 1B, C).
In the adult skeletal muscle, dystrophin is an essential struc-
tural protein that links the extracellular matrix to the actin cy-
toskeleton through assembly to the dystrophin– glycoprotein 
complex (DGC) (Figure 2A). This large multi- protein complex is 
critical for maintaining the fibre's structural integrity, the stabil-
ity of the neuromuscular synapse, and the muscle fibre's strength 
and flexibility while protecting the membrane from contraction- 
induced damage [20]. In DMD patients, loss of dystrophin leads to 
destabilisation and deterioration of the whole complex. Mutations 
in genes encoding different components of the DGC result in a 
variety of muscular dystrophies, which highlights the importance 
of this complex [21].
Dystrophin has four main domains: an N- terminal actin- 
binding domain (NTD), a central spectrin- like repeat region, 
a cysteine- rich domain (CR), which binds the DGC, and a C- 
terminal domain (CTD) (Figure 2A). Utrophin shares those 
domains with dystrophin, but there are some structural and 
mechanical differences. Both proteins differ in their lateral in-
teractions with actin [20] (Figure 2B), utrophin containing fewer 
spectrin- like repeats, and sharing only a 35% homology in the 
central domain with dystrophin. Moreover, a significant differ-
ence in the mechanical behaviour between spectrin repeats 
has been recently demonstrated [25]. Crucially, they also dif-
fer in their capacity to recruit neuronal nitric oxide synthase 
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(nNOS), which cannot be recruited by utrophin [26]. nNOS, a 
signalling protein associated with the DGC that produces nitric 
oxide (NO), is considerably reduced in dystrophic muscle fibres, 
leading to functional ischaemia due to decreased contraction- 
induced vasodilation.
While dystrophin is predominantly expressed in muscle and to 
a lesser extent in the brain, utrophin is widely expressed in sev-
eral non- skeletal muscle tissues such as lung, kidney and liver [27]. 
During foetal muscle development and at early gestational stages, 
utrophin is present at the sarcolemma of muscle fibres. After birth, 
utrophin is progressively silenced by the Ets- 2 repressor factor 
and replaced by dystrophin in adult myofibres. Thereafter, utro-
phin disappears from the membrane, and its expression is con-
fined to the neuromuscular and myotendinous junctions, where it 
participates in post- synaptic membrane maintenance and acetyl-
choline receptor clustering [28,29]. However, there is an increase 
in utrophin expression and redistribution of this protein to the sar-
colemma in the dystrophic muscle, in mature dystrophin- deficient 
fibres, regenerating fibres and dystrophin- competent revertant 
fibres found both in DMD and BMD patients, as well as in mdx 
mice [30- 32].
Utrophin overexpression in Duchenne 
muscular dystrophy
Utrophin is naturally increased at the sarcolemma of skeletal mus-
cle samples in DMD and BMD patients compared to healthy indi-
viduals [31- 33] by a repair process that also occurs in animal models 
of the disease, proposed as a compensatory mechanism to miti-
gate the lack of dystrophin. Moreover, preclinical studies indicate 
an inverse correlation between utrophin expression and disease 
severity in DMD, suggesting that utrophin could play a role as a 
dystrophin surrogate. However, while some human studies report 
a positive effect of this utrophin expression on disease severity, de-
laying its progression [34], others do not find any correlation [35].
The most widely used animal model for DMD research is the 
mdx mouse, carrying a nonsense point mutation (C- to- T tran-
sition) in exon 23 of the Dmd gene, which completely abolishes 
dystrophin expression. Despite being dystrophin- deficient, mdx 
mice have mild clinical symptoms and a long lifespan, in con-
trast to DMD patients [36]. Utrophin levels are increased at the 
sarcolemma of regenerating myofibres in the adult mdx skeletal 
muscle [37,38], but this increase may also occur independently of 
F I G U R E  1  Dystrophin and utrophin isoforms. Schematic representation of the full length and truncated dystrophin (A) and utrophin (B) 
protein isoforms including their most representative expression in tissues. (C1 and C2) Blue boxes show the specific exons, the black line 
represents the intronic regions and the transcription start sites of the different promoters are indicated by arrows within the dystrophin 
(C1) and the utrophin (C2) gene. (C1) Full- length dystrophin expression is driven by three promoters Dp427 brain, muscle and Purkinje and 
the smaller isoforms are produced from four internal promoters, Dp260, Dp140, Dp116 and Dp71. (C2) Full- length utrophin expression is 
driven by two promoters Up395- A and Up395- B and the smaller isoforms are produced from three internal promoters Up140, G- utrophin 
and Up71. Different elements of the utrophin A promoter are also specified in the panel. Created with BioRender.com
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regeneration [39]. Moreover, experimental data suggest that up-
regulation of utrophin may compensate for dystrophin deficiency. 
The potential compensatory role of utrophin has been assessed 
by generating double knockout mice for both dystrophin and 
utrophin genes (dko). These mice display a much more severe pa-
thology compared to mdx mutants, as well as multiple systemic 
degenerative changes, in addition to earlier muscle degeneration 
[40]. On the other hand, the Fiona mouse, a dystrophin- deficient 
mdx transgenic mouse that overexpresses utrophin, shows a cor-
rection of the dystrophic phenotype [38,41].
Over the years, preclinical studies have demonstrated that 
transgenic overexpression and pharmacological modulation of 
utrophin prevent skeletal muscle pathology in mdx mice. These 
studies reveal that a 2- fold increase in sarcolemmal utrophin com-
pletely rescues the mechanical function and effectively norma-
lises classical markers of DMD- related muscle damage [42,43]. 
However, even a 1.5 fold increase may be beneficial for mdx mice, 
given that utrophin localises at the sarcolemma of dystrophic fi-
bres [38]. Utrophin levels also influence mitochondrial pathology 
that contributes to oxidative stress and propagates muscle dam-
age in DMD. While utrophin deficiency aggravates the pathology, 
utrophin over- expression in the dystrophic muscle supports mi-
tochondrial function in mouse models [44]. Interestingly, another 
study focused on the role of utrophin replacing dystrophin in the 
male reproductive system discovered that full- length dystrophin 
deficiency disturbed the balance between proliferation and apop-
tosis of germ cells during spermatogenesis. In this case, there is 
also a utrophin upregulation and relocation as a compensatory 
response to dystrophin deficiency [45]. Taken together, data in 
animal models suggest that utrophin can functionally compensate 
for the lack of dystrophin.
Utrophin overexpression in patients is a promising therapeutic 
strategy for treating muscle dystrophies, since it targets the pri-
mary cause of the disease and would apply to all DMD and BMD 
patients regardless of their genetic mutation. Several approaches 
may be used to modulate utrophin levels including direct mecha-
nisms, such as gene or protein replacement, or indirect ones, such 
as transcriptional upregulation of the utrophin promoter, post- 
transcriptional regulation and protein/mRNA stabilisation (see 
Table 1).
DIREC T UTROPHIN REPL ACEMENT
Protein replacement
Direct protein replacement using recombinant full- length or trun-
cated utrophin is an attractive potential method to increase utrophin 
levels in vivo directly.
Systemic administration of a recombinant ‘micro- utrophin’ 
(μUtrn) protein combined with the cell- penetrating TAT protein 
(TAT- μUtrn), the transduction domain of the HIV- 1, can functionally 
form a μUtrophin- glycoprotein complex at the sarcolemma. This 
therapeutic strategy is able to mitigate the dystrophic phenotype of 
mdx mice, improving contractile strength [35]. TAT- μUtrn also ame-
liorates the phenotype of dystrophin/utrophin double- knockout 
F I G U R E  2  Schematic representation of dystrophin and utrophin glycoprotein complexes (DGC/UGC). (A) Dystrophin glycoprotein 
complex (DGC) and (B) utrophin glycoprotein complex (UGC) consist of dystrophin (or utrophin), syntrophins, dystrobrevins, sarcoglycans, 
sarcospan and dystroglycans distributed in cytoplasmic, transmembrane and extracellular protein complex. The cytoplasmic part includes 
α1 and β1 syntrophin isoforms and α- dystrobrevin; transmembrane part includes the sarcoglycan (α, β, γ, δ) and sarcospan complex. 
Dystroglycan complex consists in the extracellular component, α- dystroglycan (α- DG) which binds to agrin and laminin in the extracellular 
matrix and the transmembrane isoform β- dystroglycan (β- DG). Biglycan is another extracellular matrix component of the DGC/UGC that 
binds to α- dystroglycan and α- and γ- sarcoglycan [22]. Finally, β- DG binds to dystrophin or utrophin, completing the link between the 
actin- based cytoskeleton and the extracellular matrix [23]. Furthermore, utrophin is associated with large acetylcholine receptors (AChR) 
clusters at the crests of post- junctional folds in neuromuscular junctions (NMJs) [24]. Notice that the main differences between dystrophin 
and utrophin are their lateral interactions with actin and the impossibility of the UGC to recruit nNOS. Created with BioRender.com
|    SOBLECHERO- MARTÍN ET AL.714
(dko) mice, increasing skeletal muscle strength and improving activ-
ity and life span compared to placebo [36].
Although this therapeutic strategy looks promising, posology 
and administration limit its use; it would be necessary to give fre-
quent, high- dose injections that could eventually trigger a harmful 
immune response. Nevertheless, this approach might be combined 
with other therapies to increase utrophin expression.
Gene therapy
Developing gene therapy treatments for Duchene muscu-
lar dystrophy is challenging for three main reasons: first, both 
full- length DMD or UTRN genes, and even their cDNAs, are too 
large and need to be engineered into truncated (‘mini’ or ‘micro’) 
constructs in order to be packaged into adeno- associated virus 
(AAV), which are currently the most commonly used delivery 
vectors [80]; the second limitation is the possibility of inducing a 
cellular immune response to the new dystrophin generated and/
or against the AAV vector [81]; the third and major challenge 
is the difficulty to achieve body- wide transduction into human 
muscle fibres. Nevertheless, micro- dystrophin (µDys) gene ther-
apy using AAV vectors has recently been carefully optimised, 
leading to promising data in murine and canine DMD models 
[82- 84] and phase I/II clinical trials in DMD patients that are 
currently ongoing.[85]
A similar pathway has been followed in the development of 
utrophin gene therapy alternatives. Several preclinical studies using 
‘micro- utrophin’ (µUtrn) gene delivery have been reported in the last 
years; studies conducted using AAV- µUtrn in mdx mice reported 
restoration of the DGC, prevention of myofibre degeneration, nor-
malisation of serum CK levels and improvement of muscle function 
[86]. Moreover, additional studies in double knockout (dko) mice and 
canine X- linked muscular dystrophy dogs have shown that µUtrn 
improves their severe pathological dystrophic phenotype [87]. 
Modulation of utrophin expression could potentially treat many dis-
ease manifestations since AAV- μUtrn transgene administration func-
tionally replaces dystrophin in the heart and ameliorates the skeletal 
and cardiac muscle phenotype in the D2/mdx mouse model [88]. In 
addition, the ex vivo UTRN gene correction of mouse dystrophic iPS 
TA B L E  1  Mechanisms of action of potential drugs that could modulate utrophin expression
Direct mechanisms
Protein replacement TAT- μUtrn [46,47]
Gene therapy μUtrn [48]
Indirect mechanisms Acting at utrophin A promoter level Artificial zinc finger transcription factors (ZF- ATFs): Jazz [49], 
Bagly [50], Utroup [51], JZif1 [52].
Aryl hydrocarbon receptors (AhR) antagonists [53]: Ezutromid 
or SMTC0011 [54] and SMT022357[42]
Other small molecules: Nabumetone [55], Heregulin [56,57], 
Okadaic acid [58], Adiponectin [59,60]










nNOS activation L- arginine
L- citrulline
mRNA stabilisation at 5’ UTR and 3’UTR level eEF1A2/IRES- mediated translation:
Betaxolol [64,65], Pravastatina and 6α- 
methylprednisolone- 21 sodium succinate (PDN) [66]
via microRNA targeting:
Let- 7c, miR- 150, miR- 196b, miR- 296- 5p, miR- 133b
AntimiR 206
via p38 MAPK/KSRP:
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cells by µUtrn gene transfection and subsequent transplantation 
into dystrophic dko mice has also demonstrated DGC restoration 
and improvement of contractile strength [89].
Apart from all these promising results, delivering µUtrn in-
stead of µDys has a potential advantage: a lower risk to elicit an 
immune response since utrophin is naturally expressed at low 
levels in DMD patients. A recent study performed in the German 
shorthaired pointer deletional- null canine model (GSHPMD), re-
ported a strong systemic cell- mediated immune response against 
µDys but not to µUtrn. This supports the use of non- immunogenic 
utrophin- based gene therapy approach for DMD [90]. Moreover, 
overexpression of utrophin rather than dystrophin could prevent 
the use of expensive and potentially toxic adjuvant immunosup-
pressive drug therapies [86].
INDIREC T MECHANISMS FOR UTROPHIN 
OVERE XPRESSION
Transcriptional upregulation
The utrophin A promoter contains several regulatory motifs that 
could activate utrophin overexpression (Figure 3). The E- box and 
N- box motifs are essential for myogenic differentiation, and syn-
aptic expression of utrophin A [91]. The E- box motif is a bind-
ing site to myogenic factors like MyoD, myogenin, Myf5 and 
MRF4 [91]. In contrast, the N- box motif is targeted by the ETS- 
related transcription factor complex GA- binding protein (GABP) 
α/β, which is activated by nerve- derived and transcription fac-
tors. Besides, Sp binding sites targeted by Sp1 and Sp3 zinc fin-
ger transcription factors may establish a cooperative interaction 
with GABP to stimulate the utrophin promoter [92] (Figure 3). 
Moreover, it has been recently shown that utrophin A promoter 
contains a PPRE site targeted by the peroxisome- proliferator- 
activated receptor beta/delta (PPAR- β/δ). This PPRE site can also 
be stimulated through 5′ adenosine monophosphate- activated 
protein kinase (AMPK) and sirtuin 1 (SIRT- 1) signalling pathways 
that activate the peroxisome proliferator- activated receptor- 
gamma coactivator 1α (PGC- 1α) which, in turn, activates either 
PPARβ/δ or GABPα/β.
The calcineurin- nuclear factor of activated T- cells (NFAT) 
calcium- dependent signalling cascade is another pathway that pos-
itively regulates utrophin expression in the skeletal muscle. In this 
pathway, calcineurin dephosphorylates NFAT, enabling its entry into 
the nucleus and subsequent activation of the utrophin A promoter 
[93] (Figure 3).
Utrophin upregulation by stimulating utrophin A promoter ac-
tivity is a promising pharmacological approach that has been ex-
tensively investigated using different strategies. One laboratory's 
proposal was the engineered artificial zinc finger transcription fac-
tors (ZF- ATFs) called ‘Jazz’, capable of binding the utrophin A pro-
moter both in humans and mice. Systemic delivery of ZF- ATFs with 
F I G U R E  3  Utrophin A promoter 
transcriptional activation pathways. 
(A) Nucleotide sequence of the human 
UTRN gene promoter including the 
transcriptional regulatory elements: NFAT 
binding site, PPRE site, Jazz binding site, 
E- box site, N- box site and Sp binding sites. 
The arrow indicates the transcription 
starting site. (B) Representation of the 
utrophin A promoter regulatory binding 
sites, their transcriptional upregulation 
mechanisms and the compounds involved 
in utrophin upregulation through 
these signalling pathways (in blue). The 
compounds that act through promotion 
of the slow and oxidative phenotype are 
included in the purple box. Created with 
BioRender.com
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AAVs can induce a significant rescue of muscle function in dystrophic 
mdx mice through utrophin upregulation [94]. Indeed, several ‘Jazz’ 
factors have shown remarkable efficacy in ameliorating the patho-
logical phenotype of mdx mice and improving the morphology and 
plasticity of neuromuscular junctions [52]. Among them, ‘JZif1’, the 
most recently upgraded version, was developed using the backbone 
of the well- characterised Zif268/EGR1 human transcription factor 
to minimise immunogenicity and facilitate its clinical application.
Thousands of candidates from drug libraries have been tested by 
high- throughput screening (HTS) assays in order to find small mol-
ecules acting at the utrophin A promotor level. In these cell- based 
assays, a reporter gene (usually luciferase) is linked to the utrophin 
promoter [55,95]. Small molecules offer several advantages, such 
as improved delivery and bioavailability compared to gene therapy 
or protein replacement and the possibility of testing compounds al-
ready approved for clinical use. Indeed, drug repurposing to other in-
dications may accelerate their transfer to the clinic and improve their 
chances of success. In different studies, both repurposing and newly 
synthesised compounds have shown promising results at preclini-
cal level, with dose- dependent activation of the utrophin promoter 
such as nabumetone, heregulin and okadaic acid. Some of them, like 
ezutromid, have already reached clinical trials.
Nabumetone is a long- acting nonsteroidal anti- inflammatory 
drug, specifically a COX- 1/COX- 2 inhibitor that shows a preference 
for COX- 2 inhibition in vitro. It is used for pain and inflammation 
management in osteoarthritis and rheumatoid arthritis, and it is an 
example of pharmacological repurposing for DMD. HTS assays in 
C2C12 muscle cells demonstrated that nabumetone could activate 
utrophin A promoter and upregulate endogenous utrophin at mRNA 
and protein level [55].
Heregulin is a small nerve- derived grow factor capable of trans-
activating utrophin A promoter via the N- box motif. Utrophin tran-
scription induced by heregulin- mediated activation of GABPα/β 
occurs through the extracellular- signal related kinase (ERK) signalling 
pathway via the interaction of heregulin with the ErbB tyrosine ki-
nase receptor [56,57]. Intraperitoneal injections of a small heregulin 
peptide in mdx mice resulted in upregulation of utrophin, together 
with a marked functional improvement of the muscle pathology [96].
Recently, it has been shown that okadaic acid, a selective inhibi-
tor of PP1 and PP2A phosphatases, can induce utrophin A promoter 
activation during myogenesis through Sp1 phosphorylation. There 
is evidence that okadaic acid increases utrophin A mRNA levels in-
creased by around two- fold in C2C12 myoblasts, but not in myo-
tubes [58].
Ezutromid (SMTC1100) was the first orally bioavailable utro-
phin regulator that showed increased UTRN transcription. It was 
identified following a HTS strategy with a luciferase reporter- linked 
assay in murine H2K cells. Later, in vitro assays in human myoblasts 
demonstrated an increase in utrophin expression at mRNA and pro-
tein levels after ezutromid treatment, and further in vivo assays 
demonstrated that once- a- day daily- dosing of ezutromid in mdx 
mice increased utrophin levels, as well as muscle strength and resis-
tance to exercise.
After these initial results, ezutromid was developed by Summit 
Therapeutics as a potential treatment for DMD and BMD. A Phase 
1 placebo- controlled randomised clinical trial in healthy male volun-
teers and a Phase 1b placebo- controlled, randomised, double- blind 
study in boys with DMD showed that it was safe and well- tolerated. 
However, a Phase 2 clinical study (NCT02858362) failed to achieve 
both the primary (changes in leg muscle magnetic resonance pa-
rameters) and secondary endpoints (increased utrophin levels 
and decreased muscle damage). Based on these results, Summit 
Therapeutics abandoned the development program of ezutromid 
[97,98]. Recent studies have elucidated the ezutromid mechanism 
of action as an aryl hydrocarbon receptor (AhR) antagonist [53,99]. 
Similarly, other molecules that ameliorate mdx pathology like 
SMT022357 [53] or resveratrol [100] have also shown activity as 
AhR antagonists [100]. While the pathway between AhR antagonism 
and utrophin upregulation remains unknown, it seems to involve the 
stabilisation of active peroxisome proliferator- activated receptor 
gamma coactivator (PGC1α) [101]. Indeed, moderately elevated lev-
els of PGC1α ameliorate the dystrophic phenotype of mdx mice at 
the biochemical, histological and functional levels [102].
SMT022357, is a second- generation compound structurally 
related to ezutromid, sharing the same mechanism of action but 
with improved physicochemical properties and a more robust 
metabolic profile. SMT022357 administration has been associated 
with an increase in utrophin expression in skeletal, respiratory and 
cardiac muscles and prevention of the dystrophic pathology in 
mdx mice [42].
Oxidative phenotype promotion
An alternative therapeutic strategy to increase utrophin expression in 
the skeletal muscle focuses on the upregulation of the slow oxidative 
myogenic program. Promotion of the slow oxidative phenotype has 
been achieved by different transcriptional and post- transcriptional 
pathways showing utrophin overexpression (Figure 3). This strategy 
has demonstrated attenuation of the dystrophic pathology in mdx 
animals [103].
One mechanism reported is PPAR- β/δ stimulation using the syn-
thetic agonist GW501516. This molecule has also been found to 
stimulate utrophin A promoter in C2C12 muscle cells and improve 
sarcolemmal integrity in mdx mice, conferring protection against ec-
centric contraction- induced damage to muscle [104].
Chronic activation of AMPK also promotes the slow oxidative 
phenotype. Treatment of mdx mice with 5- aminoimidazole- 4- carbo
xamide- 1- β- D- ribofuranoside (AICAR) and other AMPK/PGC- 1α ac-
tivators significantly enhanced utrophin expression and have proved 
to be beneficial for the dystrophic phenotype and rescue muscle 
function [103].
One of the best known pharmacologically AMPK activators 
is metformin, a widely prescribed oral antidiabetic drug that has 
reached clinical trials for DMD in combination with the NOS mod-
ulators L- arginine and L- citrulline. Metformin increases skeletal 
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muscle utrophin content via AMPK activation and parallel or recipro-
cal increments in PGC- 1α and PPAR- δ expression [61]. Skeletal mus-
cle nNOS activation is also AMPK dependent [105]. However, the 
partial response to metformin treatment in mdx muscles combined 
with the reduced quantity of NO in some studies supports the no-
tion of combined therapy for DMD patients [61,106]. In combination 
with L- arginine, metformin showed evident amelioration of muscular 
metabolism in the first proof- of- concept pilot study (NCT02516085) 
carried out in DMD patients. Results from another study, a ran-
domised, double- blind placebo- controlled clinical trial with 47 ambu-
lant DMD patients, combining L- citrulline (an L- arginine precursor) 
and metformin (NCT01995032), showed a clinically relevant but not 
statistically significant reduction in motor function decline in a spe-
cific subgroup of patients with no apparent side effects. Therefore, 
additional clinical trials are needed to validate this approach [107]. 
Interestingly, NOS- based therapy by itself has also proved to increase 
utrophin expression. In this context, L- arginine administration in mdx 
mice resulted in a nearly 2- fold increase in utrophin in skeletal muscle, 
heart and brain, accompanied by an improvement of the dystrophic 
phenotype [108]. This study demonstrates that NOS expression has 
beneficial effects on skeletal muscle metabolism both in vitro and in 
vivo.
The hormone adiponectin protects the skeletal muscle against 
inflammation and injury via the AMPK- SIRT1- PGC- 1α signalling 
pathway. Treatment of myotubes from DMD patients with ad-
iponectin leads to downregulation of the nuclear factor kappa B 
(NF- κB) and inflammatory genes, together with an upregulation of 
utrophin [59]. Transgenic upregulation of adiponectin has demon-
strated significant beneficial properties in dystrophic mdx muscles 
[109]. Recently, an orally administrable active adiponectin receptor 
agonist, called AdipoRon, has been identified. This small synthetic 
molecule has also proved to attenuate the dystrophic phenotype in 
mdx mice offering a promising therapeutic prospect for DMD pa-
tients [60].
In the same line, obestatin, an autocrine factor that controls 
the myogenic differentiation program, induces a skeletal muscle 
shift towards a more oxidative metabolic profile through mecha-
nisms involving PGC1α and class II histone deacetylases (HDAC)/
myocyte enhancer factor- 2 (Mef2). It has been reported that 
obestatin has shown activity in stabilising the sarcolemma of mdx 
skeletal muscle through the expression of utrophin, α- syntrophin, 
β- dystroglycan and α7β1- integrin proteins, ameliorating the DMD 
phenotype [62].
Another molecule studied in preclinical assays that seems to 
upregulate utrophin through activation of the PGC- 1α pathway is 
quercetin [110]. Diet enriched with this flavonol seems to rescue 
dystrophic muscle in mdx mice and provide physiological cardiopro-
tection [111,112].
Finally, administration of the natural phenol resveratrol to 
mdx mice has also demonstrated stimulation of the SIRT1- PGC- 1α 
pathway, a significant upregulation of utrophin expression, and 
activation of the slow, oxidative myogenic program in mdx mouse 
muscle [63].
Post- transcriptional and translational events 
regulating utrophin isoform A
While utrophin upregulation at the transcriptional level has been 
widely investigated over the years, an increasing number of new 
studies support the importance of post- transcriptional and transla-
tional regulator factors of utrophin in order to find new therapeutic 
targets (Figure 4).
Utrophin full- length isoforms, A and B, have different 
5′- untranslated regions (5′- UTRs). The skeletal muscle isoform, utro-
phin A, presents an internal ribosome entry site (IRES) at its 5′UTR 
that promotes expression through IRES- dependent translational 
mechanisms [113]. IRES elements are thought to associate with the 
translational machinery, including some IRES trans- acting factors 
(ITAFs). EF1A2 has been reported as a suitable ITAF able to modulate 
the activity of the utrophin A IRES. For clarity, we refer to utrophin 
isoform A as ‘utrophin’ in the manuscript.
A recent ELISA- based HTS assay has identified at least four 
FDA- approved drugs that target eEF1A2 and cause at least a two- 
fold increase in utrophin in C2C12 muscle cells. Among them, betax-
olol and pravastatine, seem to improve the dystrophic phenotype 
of mdx mice via utrophin upregulation through IRES activation [64]. 
Moreover, in another study, utrophin protein levels are increased 
after 6α- methylprednisolone- 21 sodium succinate (PDN) treatment 
of C2C12 myotubes, suggesting that glucocorticoid's mechanism in 
muscle cells could be at least partially explained by enhancement of 
utrophin translation due to IRES activation [66]. These studies high-
light the increasing interest in using repurposed drugs to activate 
this specific pathway where endogenous utrophin levels in muscle 
are upregulated by promoting protein synthesis from already syn-
thesised transcripts.
Expression of utrophin is also regulated at its UTR 3’ end, where a 
series of cis- elements, including conserved AU- rich elements (AREs), 
modulate the stability of utrophin mRNA transcripts. Different pro-
teins can bind the AU- rich elements at the 3'- UTR and regulate 
mRNA stability either negatively or positively. For example, 3'- UTR 
repression has been attributed to miRNAs and K- homology splicing 
regulator protein (KSRP) binding to these sites.
Several miRNAs, including let- 7c, miR- 150, miR- 196b, miR- 
296- 5p, miR- 133b and miR- 206 have been shown to repress utro-
phin expression [114,115], and this has led to two therapeutic 
approaches: targeting the microRNAs directly by using antimiRs or 
blocking their binding site with site- blocking oligonucleotides (SBOs). 
Both mechanisms have shown to upregulate utrophin expression 
and improve the dystrophic phenotype in vivo. Intraperitoneal in-
jections of specific SBOs targeted to prevent let- 7c miRNA binding 
to the utrophin 3’UTR resulted in higher utrophin protein expression 
in skeletal muscles and improvement in the dystrophic phenotype in 
mdx mice [116,117]. On the other hand, a 3- month treatment with 
antiMiR- 206 increases utrophin in mdx mouse muscles compared to 
the untreated group [118].
Activating p38 mitogen- activated protein kinase (MAPK) re-
duces KSRP availability to bind utrophin's 3’UTR AREs, resulting in 
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increased stability of existing mRNAs, increased utrophin protein 
production and reduction of muscle damage [67]. At least three ap-
proved drugs and activators of p38 MAPK, heparin, celecoxib and 
anysomicin, have demonstrated a significant utrophin upregulation 
efficacy in different preclinical studies.
Heparin, which is an anticoagulant commonly used in the clinic, 
significantly increases utrophin levels both in C2C12 [67] myoblasts 
and mdx mouse dystrophic fibres, leading to substantial morpho-
logical and functional improvements [68]. In addition, combinatory 
treatment with heparin plus AICAR (an oxidative phenotype pro-
moter compound mentioned previously) has an additive effect, in-
creasing utrophin protein levels nearly 3- fold in C2C12 myoblasts 
and mdx mouse muscle [68].
Celecoxib is a nonsteroidal anti- inflammatory drug (NSAID) and 
a specific cyclo- oxygenase (COX)- 2 inhibitor used for osteoarthritis 
and rheumatoid arthritis. This drug can activate p38 MAPK signalling 
in skeletal muscle cells. Treated mdx mice revealed a 1.5- to 2- fold 
increase in utrophin expression in tibialis anterior, diaphragm and 
heart muscles, and ameliorated the dystrophic phenotype, improv-
ing muscle strength [70].
Anisomycin is an antibiotic identified by HTS assays. In 
C2C12 muscle cells, it induces a 2.5- fold increase in utrophin levels 
in vitro. It is also reported to significantly increase utrophin protein 
in the diaphragm of mdx mice treated daily with a low dose [71].
Another recent HTS screening study, targeting the 5′ and 3′ un-
translated regions (UTRs), identified 27 hit compounds capable of 
upregulating utrophin expression [119]. In this study, trichostatin A 
was identified as one of these hit compounds. Previous studies had 
demonstrated that trichostatin A could activate the utrophin pro-
moter [55]. It also increases utrophin levels post- transcriptionally by 
interacting with the 5′ and/or 3′UTR of the utrophin mRNA, result-
ing in a functional improvement of the mdx mouse. The remaining 
hits are yet to be further studied, but this is a good starting point for 
additional in vitro or in vivo assays.
Utrophin- glycoprotein complex stabilisation
Utrophin complex stabilisation is an alternative mechanism that 
has gained strength in the last years with promising results. One 
example of this approach is the extracellular matrix biglycan, a 
proteoglycan that plays an essential role in muscle development. 
Biglycan is a component of the DGC/UGC, where it regulates the 
expression of sarcoglycans, dystrobrevins, syntrophins and nNOS, 
by recruiting utrophin to the plasma membrane. In humans and 
mice, biglycan is most highly expressed in immature and regen-
erating muscle [22]. Several studies in mdx mice have shown that 
systemically administered recombinant human biglycan upregu-
lates utrophin and other DGC components at the sarcolemma, 
while ameliorating muscle pathology and improving muscle 
structure and function with no obvious toxicity.[72,73] Tivorsan 
Pharmaceuticals is currently developing a potential treatment for 
DMD and BMD called TVN- 102, a recombinant human biglycan 
that can be systemically administrated [120]. The FDA granted 
TVN- 102 orphan drug status in 2016. Meanwhile, Tivorsan 
Pharmaceuticals has completed pharmacological studies in rats 
and non- human primates in order to determine the safe starting 
dose in clinical trials, planned to be initiated soon.
Similarly, the recombinant human protein laminin- 111 
(rhLAM111), another extracellular matrix protein, has shown to 
upregulate other proteins such as utrophin and α7β1 integrin, both 
capable of restoring muscle cell adhesion and stimulating muscle 
regeneration in DMD patients. Research in mdx mouse has demon-
strated that rhLAM111 can strengthen muscles and improve muscle 
F I G U R E  4  Therapeutic strategies for 
post- transcriptional utrophin upregulation. 
Representation of the post- transcriptional 
pathways to enhance utrophin expression: 
mRNA stabilisation, nNOS activation and 
protein stabilisation and the compounds 
acting through these mechanisms (in blue). 
Created with BioRender.com
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function. The underlying mechanisms of action reported involved 
elevated levels of different compensatory proteins and utrophin 
increases of 1.3- fold. However, it is not completely clear if this in-
crease in utrophin is sufficient to induce a phenotypical improve-
ment [76,77]. Indeed, some studies claim that higher utrophin 
concentrations (1.5/2- fold increase) are necessary to achieve a ther-
apeutic effect [38]. In any case, recent results show that laminin pre-
vents muscle disease progression in the golden retriever muscular 
dystrophy (GRMD) dog model of DMD and, thus, it could be a novel 
protein therapy for DMD patients [120].
Overexpression of CT- GalNAc 2 (cytotoxic T- cell N- 
acetylgalactosamine transferase), or Galgt2 protein, has been 
shown to increase synapse- associated proteins, including utro-
phin, and enhances its transportation to the sarcolemma [75]. 
AAV- mediated GALGT2 gene delivery has shown protection in 
both wild- type and dystrophin- mdx skeletal myofibres from ec-
centric contraction- induced injury. It also prevents muscular 
dystrophy and ameliorates the phenotype in different animal 
models [121,122]. Following these studies, the first clinical trial 
of AAVrh74- mediated GALGT2 gene delivery in DMD boys began 
recruiting in 2018.
CONCLUDING REMARKS
Utrophin upregulation is a promising therapeutic approach, appli-
cable for all DMD and BMD patients, that has demonstrated func-
tionally compensation for the lack of dystrophin, improving the 
pathological phenotype in different dystrophic models.
Many pathways involved in utrophin expression are currently 
being explored, and some of them have only started to be eluci-
dated. There are high expectations in many compounds that have 
demonstrated efficacy in activating utrophin expression in preclin-
ical assays. However, the amount of utrophin required by dystro-
phic patients to achieve a relevant clinical benefit remains to be 
determined. Hopefully, soon some of these molecules will reach 
clinical studies and become therapeutic options for the Duchenne 
community.
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